
Evolus (EOLS) Stock Forecast & Price Target
Evolus (EOLS) Analyst Ratings
Bulls say
Evolus is well-positioned in the growing medical aesthetics market with its two commercially available products and a strong pipeline, including the first liquid-formulation toxin. The company is also expanding globally, increasing its potential market reach. Management's positive outlook on the neurotoxin market and the tailwinds of facial volume loss in the HA gel market further support the positive outlook. The company's strong balance sheet with access to additional funding also provides financial stability for future growth.
Bears say
Evolus is facing several challenges that warrant a negative outlook, including slower-than-expected market growth for its injectables and competition from established brands like Voluma. There are also concerns about the company's ability to meet its revenue guidance and sustain profitability in the long term, as well as potential risks related to consumer spending, commercial execution, and regulatory delays. Furthermore, the company's recent price target downgrade highlights investor skepticism about its future earnings potential and market differentiation.
This aggregate rating is based on analysts' research of Evolus and is not a guaranteed prediction by Public.com or investment advice.
Evolus (EOLS) Analyst Forecast & Price Prediction
Start investing in Evolus (EOLS)
Order type
Buy in
Order amount
Est. shares
0 shares